We are live on ! Find out more
LXRX icon

Lexicon Pharmaceuticals
LXRX

121 hedge funds and large institutions have $1.29B invested in Lexicon Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 45 increasing their positions, 37 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

86% more call options, than puts

Call options by funds: $4.86M | Put options by funds: $2.62M

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

37% more capital invested

Capital invested by funds: $940M → $1.29B (+$351M)

22% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 37

1.11% less ownership

Funds ownership: 103.95% → 102.84% (-1.1%)

4% less funds holding

Funds holding: 126 → 121 (-5)

27% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 15

Holders
121
Holders Change
-5
Holders Change %
-3.97%
% of All Funds
2.77%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
11
Increased
45
Reduced
37
Closed
15
Calls
$4.86M
Puts
$2.62M
Net Calls
+$2.25M
Net Calls Change
+$3.14M

Top Buyers

1
AG
Artal Group
Luxembourg
+$20.1M
2
Millennium Management
Millennium Management
New York
+$4.39M
3
BlackRock
BlackRock
New York
+$2M
4
PCM
Price Capital Management
Louisiana
+$1.38M
5
CLM
ClearBridge LLC (Maryland)
Maryland
+$1.31M

Top Sellers

1
UIM
USS Investment Management
United Kingdom
-$22.6M
2
State Street
State Street
Massachusetts
-$6.86M
3
TCM
Tekla Capital Management
Massachusetts
-$1.98M
4
PA
Pinnacle Associates
New York
-$1.19M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
-$1.13M
Name Holding Trade Value Shares
Change 		Change in
Stake
AG
1
Artal Group
Luxembourg
$723M +$20.1M +1,966,214 +3%
Fidelity Investments
2
Fidelity Investments
Massachusetts
$190M +$368K +36,006 +0.2%
BlackRock
3
BlackRock
New York
$53.1M +$2M +195,461 +5%
UL
4
Ulys LLC
New York
$51.9M – – –
UBS AM
5
UBS AM
Illinois
$47.7M -$393K -38,377 -1%
Vanguard Group
6
Vanguard Group
Pennsylvania
$45.1M +$197K +19,242 +0.5%
NMC
7
NEA Management Company
Maryland
$28.6M – – –
State Street
8
State Street
Massachusetts
$24M -$6.86M -670,584 -25%
SGA
9
Sector Gamma AS
Norway
$10.4M +$81.9K +8,010 +0.9%
PA
10
Pinnacle Associates
New York
$8.1M -$1.19M -115,860 -15%
Marshall Wace
11
Marshall Wace
United Kingdom
$7.81M -$877K -85,727 -12%
Northern Trust
12
Northern Trust
Illinois
$7.01M +$126K +12,289 +2%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$6.34M +$782K +76,428 +17%
Millennium Management
14
Millennium Management
New York
$5.15M +$4.39M +429,353 New
TRSOTSOK
15
Teachers Retirement System of the State of Kentucky
Kentucky
$5.01M – – –
CS
16
Candriam SCA
Luxembourg
$4.46M +$1.06M +104,000 +39%
Deutsche Bank
17
Deutsche Bank
Germany
$3.98M -$977K -95,480 -22%
PAMU
18
Pictet Asset Management (UK)
United Kingdom
$3.52M -$1.13M -110,000 -27%
Norges Bank
19
Norges Bank
Norway
$3.2M – – –
Two Sigma Investments
20
Two Sigma Investments
New York
$3.14M +$794K +77,660 +42%
Wellington Management Group
21
Wellington Management Group
Massachusetts
$2.93M -$868K -84,913 -26%
Charles Schwab
22
Charles Schwab
California
$2.89M +$148K +14,426 +6%
PP
23
PDT Partners
New York
$2.86M +$11.2K +1,099 +0.5%
Bank of New York Mellon
24
Bank of New York Mellon
New York
$2.35M -$77.9K -7,617 -4%
Renaissance Technologies
25
Renaissance Technologies
New York
$2.31M -$375K -36,660 -16%
1
2 3 4 5

LXRX Hedge Fund Activity: Q2 2018 in Review

121 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q2 2018, worth a combined $1.29B — up 37% from $940M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of LXRX and 11 opened new positions — a net loss of 4 holders — while 37 trimmed existing stakes and 45 added.

The largest buyer was Artal Group, adding an estimated $20.1M. The largest seller was USS Investment Management, exiting entirely with an estimated $22.6M sold.

  • 121 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q2 2018, down from 126 in Q1 2018.
  • Funds reported $1.29B of Lexicon Pharmaceuticals stock for Q2 2018, up 37% quarter-over-quarter.
  • 11 funds opened new Lexicon Pharmaceuticals positions in Q2 2018 and 15 closed out, a net change of -4 holders.
  • The largest Lexicon Pharmaceuticals buyer in Q2 2018 was Artal Group, an estimated $20.1M added.
  • The largest Lexicon Pharmaceuticals seller in Q2 2018 was USS Investment Management, an estimated $22.6M sold.

Based on aggregated 13F filings for Q2 2018.